IL271966B2 - A universal vaccine based on shared neoantigens for the prevention and treatment of cancer (MICRO SATELLITE INSTABLE (MSI)) - Google Patents

A universal vaccine based on shared neoantigens for the prevention and treatment of cancer (MICRO SATELLITE INSTABLE (MSI))

Info

Publication number
IL271966B2
IL271966B2 IL271966A IL27196620A IL271966B2 IL 271966 B2 IL271966 B2 IL 271966B2 IL 271966 A IL271966 A IL 271966A IL 27196620 A IL27196620 A IL 27196620A IL 271966 B2 IL271966 B2 IL 271966B2
Authority
IL
Israel
Prior art keywords
cancer
fsps
fsp
cvp
collection
Prior art date
Application number
IL271966A
Other languages
English (en)
Hebrew (he)
Other versions
IL271966B1 (en
IL271966A (en
Inventor
Nicosia Alfredo
Lahm Armin
Scarselli Elisa
LEONI Guido
Original Assignee
Nouscom Ag
Nicosia Alfredo
Lahm Armin
Scarselli Elisa
LEONI Guido
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nouscom Ag, Nicosia Alfredo, Lahm Armin, Scarselli Elisa, LEONI Guido filed Critical Nouscom Ag
Publication of IL271966A publication Critical patent/IL271966A/en
Publication of IL271966B1 publication Critical patent/IL271966B1/en
Publication of IL271966B2 publication Critical patent/IL271966B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10Sequence alignment; Homology search
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5152Tumor cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL271966A 2017-07-12 2018-07-12 A universal vaccine based on shared neoantigens for the prevention and treatment of cancer (MICRO SATELLITE INSTABLE (MSI)) IL271966B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17181026 2017-07-12
PCT/EP2018/069032 WO2019012082A1 (en) 2017-07-12 2018-07-12 UNIVERSAL VACCINE BASED ON SHARED TUMOR NEO-ANTIGENS FOR THE PREVENTION AND TREATMENT OF MICRO-SATELLITE INSTABILITY CANCER (MSI)

Publications (3)

Publication Number Publication Date
IL271966A IL271966A (en) 2020-02-27
IL271966B1 IL271966B1 (en) 2024-09-01
IL271966B2 true IL271966B2 (en) 2025-01-01

Family

ID=59366234

Family Applications (1)

Application Number Title Priority Date Filing Date
IL271966A IL271966B2 (en) 2017-07-12 2018-07-12 A universal vaccine based on shared neoantigens for the prevention and treatment of cancer (MICRO SATELLITE INSTABLE (MSI))

Country Status (19)

Country Link
US (1) US11578109B2 (enExample)
EP (1) EP3652606B1 (enExample)
JP (1) JP7274223B2 (enExample)
KR (1) KR102709778B1 (enExample)
CN (1) CN111328420B (enExample)
AU (1) AU2018298849B2 (enExample)
BR (1) BR112020000590A2 (enExample)
CA (1) CA3069047A1 (enExample)
DK (1) DK3652606T5 (enExample)
ES (1) ES2940087T3 (enExample)
FI (1) FI3652606T3 (enExample)
HU (1) HUE061840T2 (enExample)
IL (1) IL271966B2 (enExample)
MX (1) MX2020000413A (enExample)
NZ (1) NZ759940A (enExample)
PL (1) PL3652606T3 (enExample)
PT (1) PT3652606T (enExample)
SG (1) SG11202000250PA (enExample)
WO (1) WO2019012082A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220349010A1 (en) 2018-07-26 2022-11-03 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
IL280112B2 (en) 2018-07-26 2025-11-01 Curevac Netherlands B V Cancer vaccines for breast cancer
CA3106567A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for kidney cancer
IL280113B2 (en) 2018-07-26 2025-11-01 Curevac Netherlands B V Cancer vaccines for uterine cancer
US12005104B2 (en) 2018-07-26 2024-06-11 Curevac Netherlands B.V. Cancer vaccines for colorectal cancer
WO2020022903A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US20220008525A1 (en) * 2019-02-07 2022-01-13 Arizona Board Of Regents On Behalf Of Arizona State University Cancer specific frameshift vaccines
CN114980920A (zh) 2019-11-18 2022-08-30 詹森生物科技公司 基于突变体calr和jak2的疫苗及其用途
US20230212243A1 (en) * 2020-05-12 2023-07-06 Institut Curie Neoantigenic Epitopes Associated with SF3B1 Mutations
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022216856A1 (en) * 2021-04-06 2022-10-13 Board Of Regents, The University Of Texas System Methods and compositions comprising mhc class i peptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187508A2 (en) * 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
AU2003232485A1 (en) * 2002-04-18 2003-10-27 Mtm Laboratories Ag Neopeptides and methods useful for detection and treatment of cancer
WO2004092338A2 (en) * 2003-04-11 2004-10-28 Diadexus, Inc. Compositions, splice variants and methods relating to cancer specific genes and proteins
CN1824325A (zh) * 2005-12-16 2006-08-30 武汉大学 人乳头病毒dna嵌合疫苗及制备方法和应用
EP2687540A1 (en) * 2006-10-17 2014-01-22 Oncotherapy Science, Inc. Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
TW201102081A (en) * 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
WO2010136598A1 (en) 2009-05-29 2010-12-02 Morphosys Ag A collection and methods for its use
JP2013523084A (ja) * 2010-04-09 2013-06-17 オンコセラピー・サイエンス株式会社 Cdca5ペプチドおよびそれを含むワクチン
ES2575980T3 (es) * 2011-03-24 2016-07-04 Institut National De La Santé Et De La Recherche Médicale (Inserm) Mutante de HSP110 dominante negativo y su uso en el pronóstico y el tratamiento de cánceres
KR102015648B1 (ko) * 2011-08-12 2019-08-28 온코세라피 사이언스 가부시키가이샤 Mphosph1 펩티드 및 이를 포함한 백신
JP5890769B2 (ja) * 2012-12-13 2016-03-22 ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクRuprecht−Karls−Universitaet Heidelberg がんの予防及び治療のためのmsi特異的なフレームシフトペプチド(fsp)
KR101810840B1 (ko) * 2012-12-13 2017-12-20 루프레히트-칼스-유니페어지테트 하이델베르크 암의 예방 및 치료용 msi-특이적 프레임쉬프트 펩티드(fsp)
US9205140B2 (en) * 2012-12-13 2015-12-08 Ruprecht-Karls-Universität MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer
US20150337388A1 (en) * 2012-12-17 2015-11-26 Virginia Tech Intellectual Properties, Inc. Methods and compositions for identifying global microsatellite instability and for characterizing informative microsatellite loci
WO2015112930A1 (en) * 2014-01-27 2015-07-30 Yale University Novel methods of identifying patients responsive to immunotherapeutic strategies
CN106350578A (zh) * 2015-07-13 2017-01-25 中国人民解放军第二军医大学 Ny-eso-1在微卫星不稳定性肠癌的诊断和治疗中的应用
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187508A2 (en) * 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SCHWITALLE YVETTE ET AL, " IMMUNOGENIC PEPTIDES GENERATED BY FRAMESHIFT MUTATIONS IN DNA MISMATCH REPAIR-DEFICIENT CANCER CELLS.", 25 November 2004 (2004-11-25) *
SHEN LUHUI ET AL, " ABSTRACT 469: PROGRESS TOWARDS DEVELOPING A UNIVERSAL, PROPHYLACTIC CANCER VACCINE.", 1 April 2013 (2013-04-01) *
WOERNER S M ET AL, " SYSTEMATIC IDENTIFICATION OF GENES WITH CODING MICROSATELLITES MUTATED IN DNA MISMATCH REPAIR-DEFICIENT CANCER CELLS", 1 October 2001 (2001-10-01) *

Also Published As

Publication number Publication date
EP3652606B1 (en) 2023-01-11
HUE061840T2 (hu) 2023-08-28
PL3652606T3 (pl) 2023-04-24
KR20200029443A (ko) 2020-03-18
CN111328420B (zh) 2023-07-25
IL271966B1 (en) 2024-09-01
ES2940087T3 (es) 2023-05-03
CN111328420A (zh) 2020-06-23
RU2019144505A3 (enExample) 2021-08-12
AU2018298849B2 (en) 2022-07-14
CA3069047A1 (en) 2019-01-17
FI3652606T3 (fi) 2023-03-16
DK3652606T5 (da) 2024-08-26
DK3652606T3 (da) 2023-03-13
PT3652606T (pt) 2023-03-16
NZ759940A (en) 2023-07-28
IL271966A (en) 2020-02-27
AU2018298849A1 (en) 2020-01-02
JP7274223B2 (ja) 2023-05-16
SG11202000250PA (en) 2020-02-27
EP3652606A1 (en) 2020-05-20
JP2020532288A (ja) 2020-11-12
RU2019144505A (ru) 2021-08-12
MX2020000413A (es) 2020-09-28
BR112020000590A2 (pt) 2020-07-14
WO2019012082A1 (en) 2019-01-17
US20200222519A1 (en) 2020-07-16
US11578109B2 (en) 2023-02-14
WO2019012082A9 (en) 2019-05-02
KR102709778B1 (ko) 2024-09-26

Similar Documents

Publication Publication Date Title
US11578109B2 (en) Universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (MSI) cancers
RU2644201C2 (ru) Вакцины против hpv
US12064477B2 (en) HPV vaccine
RU2019119272A (ru) Вирусная доставка неоантигенов
JP2004506410A (ja) 合成ぺプチド及びその使用
JP2003509035A (ja) ポリエピトープポリペプチドをコードする核酸
Sundaram et al. A novel multivalent human CTL peptide construct elicits robust cellular immune responses in HLA-A∗ 0201 transgenic mice: implications for HTLV-1 vaccine design
CN112512568A (zh) 遗传修饰的重组痘苗安卡拉(rmva)疫苗改善的稳定性及其制备方法
US20070104685A1 (en) Synthetic gene encoding human carcinoembryonic antigen and uses thereof
CN120857939A (zh) Egfr疫苗盒
HK40029760A (en) A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers
HK40029760B (en) A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers
AU2016335070B2 (en) Polyepitope constructs for use in immunotherapy
CN121627808A (zh) Hpv-52型e6蛋白的特异性ctl表位肽及其应用
Bazhan et al. Design of Artificial Immunogens Containing T-Cell Epitopes of Ebola Virus Proteins
CA3109541A1 (en) Teleost invariant chain cancer vaccine
ZA200508013B (en) Synthetic gene encoding human carcinoembryonic antigen and use thereof
HK1002055B (zh) 多表位疫苗
HK1002055A1 (en) Polyepitope vaccines